

# UCB S.A.

ISIN: BE0003739530

WKN: 992418

Asset Class: Stock

## Company

2024/06/28 17:35:29

Price

**138.70**

EUR

Difference



0.91%(1.25)



## Contact Details

UCB SA

Tel: +32-2-559-99-99

--

Fax: +

Allée de la Recherche, 60

Web: <http://www.ucb.com>

1070 Brüssel

E-mail: [contactucb@ucb.com](mailto:contactucb@ucb.com)

## Company Profile

UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	3,444,000,000		3,304,000,000		3,710,000,000	
Common stock capital		584,000,000		584,000,000		584,000,000
Fixed assets	12,095,000,000		12,564,000,000		10,500,000,000	
Equity capital of a company		8,975,000,000		9,064,000,000		8,386,000,000
Cash and cash equivalents	861,000,000		899,000,000		1,263,000,000	
Accrued liabilities		439,000,000		333,000,000		503,000,000
Other assets	-		-		-	
Current liabilities		2,616,000,000		3,112,000,000		2,824,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		3,948,000,000		3,692,000,000		3,000,000,000
Different income		-		-		-
Other liabilities		227,000,000		344,000,000		238,000,000
Total assets	15,539,000,000	15,539,000,000	15,868,000,000	15,868,000,000	14,210,000,000	14,210,000,000

## Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	9,083	8,703	8,561
Equity ratio	57.76%	57.12%	59.01%
Debt-equity ratio	73.14%	75.07%	69.45%

## Others

	2023	2022	2021
Tax Expense Rate	22.22%	17.81%	13.87%

## Income statement

	2023	2022	2021
<b>Turnover</b>	5,252,000,000	5,517,000,000	5,777,000,000
<b>Net income</b>	343,000,000	420,000,000	1,056,000,000
<b>EBIT</b>	558,000,000	578,000,000	1,269,000,000
<b>Operating income before taxes</b>	441,000,000	511,000,000	1,226,000,000
<b>Cash Flow</b>	617,000,000	1,045,000,000	1,490,000,000
<b>Net interest income</b>	-117,000,000	-67,000,000	-43,000,000
<b>Research and development expenses</b>	1,630,000,000	1,670,000,000	1,629,000,000
<b>Income taxes</b>	98,000,000	91,000,000	170,000,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	578,223	633,919	674,804

## Board of Directors

Jonathan Peacock	Chairman of Supervisory Board
Dame Davies	Member of Supervisory Board
Dolca Thomas	Member of Supervisory Board
Jan Berger	Member of Supervisory Board
Susan Gasser	Member of Supervisory Board
Charles-Antoine Janssen	Member of Supervisory Board
Cyril Janssen	Member of Supervisory Board
Jonkheer Cédric van Rijckevorsel	Member of Supervisory Board
Maëlys Castella	Member of Supervisory Board
Nefertiti Greene	Member of Supervisory Board
Pierre Gurdjian	Member of Supervisory Board
Rodolfo Savitzky	Member of Supervisory Board
Ulf Arne Wiinberg	Member of Supervisory Board

## Members of Management Board

Jean-Christophe Tellier	Chairman of Managing Board
Alistair Henry	Member of Executive Committee
Denelle Waynick Johnson	Member of Executive Committee
Emmanuel Caeymaex	Member of Executive Committee
Fiona du Monceau	Member of Executive Committee
Iris Löw-Friedrich	Member of Executive Committee
Jean Luc Fleurial	Member of Executive Committee
Kirsten Lund-Jurgensen	Member of Executive Committee
Sandrine Dufour	Member of Executive Committee